The AlphaFold team’s pharmaceutical company secures $2.1 billion in Series B funding, with clinical trials launching by the end of the year

CoinWorld News, the pharmaceutical company Isomorphic Labs, a team behind AlphaFold, has completed a $2.1 billion Series B funding round, with Thrive Capital leading two consecutive rounds, and investments from Alphabet, GV, and new investors including Abu Dhabi’s sovereign fund MGX, Singapore’s Temasek, CapitalG, and the UK Sovereign AI Fund. Including last year’s $600 million Series A, the company’s external funding has totaled $2.7 billion. Isomorphic Labs became independent from DeepMind in 2021, with Demis Hassabis, co-founder of DeepMind, serving as CEO. The company’s core weapon is the AI drug design engine Isodde, capable of applying AI models to small molecule and biologic design. It has already signed cooperation agreements with Eli Lilly, Novartis, and Johnson & Johnson, with potential milestone payments totaling approximately $3 billion. Isomorphic Labs expects the first AI-designed drugs to enter clinical trials by the end of 2026, later than Hassabis’s previous target of the end of 2025. If progress is on schedule, this will be a key validation of AlphaFold technology’s commercial application in the pharmaceutical industry.